PSIP

Adverse Drug Events (ADE) due to product safety problems, and medication errors due to human factors (HF) are a major Public Health issue. They endanger the patients¿ safety and originate considerable extra hospital costs. Healthcare ICT applications should help reducing the prevalence of preventable ADE, by providing healthcare professionals and patients with relevant knowledge (guidelines, recommendations, etc.).

But their efficiency is impeded by two major drawbacks:

  • lack of reliable knowledge about ADE
  • poor ability of ICT solutions to deliver contextualised knowledge focused on the problem at hand, aggravated by a poor consideration of causative HF.

The objective of the project Patient Safety through Intelligent Procedures in Medication (PSIP) is (1) to facilitate the systematic production of epidemiological knowledge on ADE and (2) to ameliorate the entire medication cycle in a hospital environment.

The first sub-objective, SO, is to innovatively produce knowledge on ADE: to know, as exactly as possible, per hospital, their number, type, consequences and causes, including HF. Data Mining of the structured hospital data bases, and Semantic Mining of Data Collections of free-texts (letters, reports), will give a list of observed ADEs, with frequencies and probabilities, thus giving a better understanding of potential risks.

The second SO is to develop a set of innovative knowledge based on the mining results and to deliver a contextualised knowledge fitting the local risk parameters, in the form of alerts and decision support functions. This knowledge will be implemented in a PSIP-platform independently of existing ICT applications. These applications will connect to the platform to access and integrate the knowledge in their local system. The design and development cycle of the PSIP solution will be HF oriented.

Dissemination plans will be developed taking into account other uses (medical devices, primary and tertiary Healthcare).

For further information, please visit:
http://www.psip-project.eu

Project co-ordinator:
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE

Partners:

  • KITE SOLUTIONS S.N.C. DI DUNNE CATHERINE E C.
  • AALBORG UNIVERSITET
  • ORACLE FRANCE SAS
  • REGION HOVEDSTADEN
  • IBM DANMARK A/S
  • CENTRE HOSPITALIER DE DENAIN
  • VIDAL S.A.
  • IDEEA ADVERTISING SRL
  • EVALAB
  • MEDASYS SA
  • CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN
  • ARISTOTLE UNIVERSITY OF THESSALONIKI
  • UMIT - PRIVATE UNIVERSITAET FUER GESUNDHEITSWISSENSCHAFTEN, MEDIZINISCHE INFORMATIK UND TECHNIK GESELLSCHAFT MBH

Timetable: from 01/2008 – to 04/2011

Total cost: € 9.946.770

EC funding: € 7.268.981

Programme Acronym: FP7-ICT

Subprogramme Area: Advanced ICT for risk assessment and patient safety

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...